-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 29, Shanghai Sunshine Pharmaceutical Procurement Network officially released the "National Drug Centralized Procurement Document", which involved 56 varieties, compared with the first two batches (25 varieties, 32 varieties) significantly expanded, and covered with a number of billion-level varieties such as satan, metformin, Capethabin and so on.
schedule, the third batch of collections is expected to open on 20 August.
on the whole, the third batch of collection rules are similar to the second batch collection rules, but there has been an increase in the maximum number of shortlisted enterprises (up to eight selected) and special provisions have been made for some antibiotic varieties.
industry insiders believe that the future volume procurement will become the new normal, it is recommended to pay attention to two pharmaceutical circuits.
one is the enterprise with imitation class, raw materials - preparation integration, including China Biopharmaceuticals, Hengrui Pharmaceuticals, Collon Pharmaceuticals, Huahai Pharmaceuticals, Borui Pharmaceuticals and other consistency evaluation through varieties, a large number of enterprises.
from the third round of collection involved in the 56 varieties of the evaluation enterprise situation, China Biopharmaceutical with 9 involved in the evaluation of the varieties to lead;
in addition, Huahai Pharmaceuticals holds three over-rated varieties involved.
it is understood that Hengrui Pharmaceuticalin in the first half of this year to obtain innovative pharmaceutical preparations production batch 3, generic pharmaceutical preparation production batch 1, 37 clinical approval of innovative drugs, 3 varieties of consistency evaluation approval, complete the consistency evaluation of 2 products declaration.
the company has a company has Irisib, thiaphin, pyrith, Carelli zuma and toluene-sulphate rematonic and other 6 listed class 1 new drug, PARP inhibitors declared NDA, if the smooth progress is expected to be approved within the year, more than 40 drugs into the clinical stage, rich in the pipeline reserves for long-term development to lay a solid foundation.
with the first half of PD-1 new liver cancer, esophageal cancer, non-small cell lung cancer three indications approved, the second half of PD-1 sales growth is expected to further accelerate.
second is in the context of the normalization of collection, upstream raw material bargaining capacity to improve, the industry suggested to pay attention to Fuxiang Pharmaceuticals, Plo Pharmaceuticals and other related API labels.
, Fuxiang Pharmaceuticals is one of the few domestic from the starting raw materials to the downstream API whole industrial chain layout of carbon penene-type Pernan series of products important manufacturers.
company's main business for the characteristics of antibacterial API and its intermediates of research and development, production and sales, including the Shubatan series, taprene bartenain inhibitor apiandic drugs and intermediates, carbon penicillin antibacterial API and intermediates and other three series of products.
the current company is also extending to the preparation business, the semi-annual report shows that Fuxiang (Dalian) approved by the State Drug Administration issued the AgaQuban injection "drug registration approval", in China has been included in the 2019 version of the national health insurance directory.
this also means that the company's layout in the field of preparation sits a step further.
Propharmaceutical industry as the domestic API leader, its API-preparation integration advantages are gradually emerging.
for example, its ANDA project - hydrochloric acid amphetamine slow release tablets have been approved by the United States FDA to market;
industry expects that the integration of API preparations will open up more room for the company's development.
.